Trade Name: Ditropan

Generic Name: Oxybutynin

Pt Weight: 69kg

Classification: urinary tract antispasmodic

Indications:
Urinary symptoms that may be associated with neurogenic bladder including:
Frequent urination,
Urgency,
Nocturia,
Urge incontinence.
Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
Why is your patient taking this drug?
No clue, shes NPO and hasnt eliminated all day
Standard doses and routes:
PO: (Adults) Immediate-release tablets 5 mg 23 times daily (not to exceed 5 mg 4 times daily)
(may start with 2.5 mg 23 times daily in elderly).
Patient Dose: 2.5mg
Adverse Reactions & Side Fx:

Patient/Family Teaching:

CNS: dizziness, drowsiness, agitation, confusion,

hallucinations, headache
EENT: blurred vision, hoarseness
CV: chest pain, edema, tachycardia
GI: constipation, dry mouth, nausea, abdominal pain, anorexia,
diarrhea, dysphagia
GU: thirst, urinary retention
Derm: sweating, hot flushes, transdermal only: application
site reactions, pruritus
Metabolic: hyperthermia
Misc: ANAPHYLAXIS, ANGIOEDEMA
* CAPITALS indicate life-threatening.
Italics indicate most frequent.

1. Instruct patient to take

oxybutinin as directed.
Take missed doses as
soon as remembered
unless almost time for next
dose. Advise patient to
read Information for the
Patient prior to beginning
therapy and with each Rx
refill in case of new
information.
2. May cause drowsiness or
blurred vision. Advise
patient to avoid driving and
other activities requiring
alertness until response to
medication is known.
3. Advise patient to avoid
concurrent use of alcohol
and other CNS depressants
while taking this

Contraindications:
Hypersensitivity;
Uncontrolled angle-closure glaucoma;
Intestinal obstruction or atony;
Urinary retention.

Nursing Implications:
1. Before giving drug, get confirmation of neurogenic bladder
by cystometry and rule out partial intestinal obstruction in
patients with diarrhea, especially those with colostomy or
ileostomy
2. Drug may aggravate symptoms of hyperthyroidism, CAD,
heart failure, arrhythmias, tachycardia, hypertension, or
prostatic hyperplasia
3. Obtain periodic cystometry as directed to evaluate
response to therapy
4. Monitor patient for residual urine after voiding
Lab Test Considerations: None reported

and other CNS depressants

while taking this
medication.
4. Instruct patient that
frequent rinsing of mouth,
good oral hygiene, and
sugarless gum or candy
may decrease dry mouth.
Health care professional
should be notified if mouth
dryness persists >2 wk.
5. Advise patient to stop
taking oxybutinin and
notify health care
professional immediately if
signs of angioedema and/
or anaphylaxis (swelling of
face, tongue, or throat;
rash; dyspnea).
6. Inform patient that
oxybutynin decreases the
body's ability to perspire.
Avoid strenuous activity in
a warm environment
because overheating may
occur.